Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrimeC in ALS
NCT04090684Phase 1Completed
- Sponsor
- NeuroSense Therapeutics
- Start
- Dec 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PrimeC in amyotrophic lateral sclerosis (ALS), sponsored by NeuroSense Therapeutics. Primary endpoints: Number of participants with one or more treatment-emergent adverse events at 15 months, Number of patients who discontinued treatment prematurely at 15 months and 2 more. Started Dec 2019; status: completed.
02
Drugs
PrimeC
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04090684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090684.